Identifying molecular tags selectively retained on the surface of brain endothelial cells to generate artificial targets for therapy delivery
-
Published:2023-12-06
Issue:1
Volume:20
Page:
-
ISSN:2045-8118
-
Container-title:Fluids and Barriers of the CNS
-
language:en
-
Short-container-title:Fluids Barriers CNS
Author:
Porro Giulia Maria,Lorandi Italo,Liu Xueying,Kataoka Kazunori,Battaglia Giuseppe,Gonzalez-Carter Daniel
Abstract
AbstractCurrent strategies to identify ligands for brain delivery select candidates based on preferential binding to cell-membrane components (CMC) on brain endothelial cells (EC). However, such strategies generate ligands with inherent brain specificity limitations, as the CMC (e.g., the transferrin receptor TfR1) are also significantly expressed on peripheral EC. Therefore, novel strategies are required to identify molecules allowing increased specificity of therapy brain delivery. Here, we demonstrate that, while individual CMC are shared between brain EC and peripheral EC, their endocytic internalization rate is markedly different. Such differential endocytic rate may be harnessed to identify molecular tags for brain targeting based on their selective retention on the surface of brain EC, thereby generating ‘artificial’ targets specifically on the brain vasculature. By quantifying the retention of labelled proteins on the cell membrane, we measured the general endocytic rate of primary brain EC to be less than half that of primary peripheral (liver and lung) EC. In addition, through bio-panning of phage-displayed peptide libraries, we unbiasedly probed the endocytic rate of individual CMC of liver, lung and brain endothelial cells. We identified phage-displayed peptides which bind to CMC common to all three endothelia phenotypes, but which are preferentially endocytosed into peripheral EC, resulting in selective retention on the surface of brain EC. Furthermore, we demonstrate that the synthesized free-form peptides are capable of generating artificial cell-surface targets for the intracellular delivery of model proteins into brain EC with increasing specificity over time. The developed identification paradigm, therefore, demonstrates that the lower endocytic rate of individual CMC on brain EC can be harnessed to identify peptides capable of generating ‘artificial’ targets for the selective delivery of proteins into the brain vasculature. In addition, our approach identifies brain-targeting peptides which would have been overlooked by conventional identification strategies, thereby increasing the repertoire of candidates to achieve specific therapy brain delivery.
Funder
“la Caixa” Foundation Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Developmental Neuroscience,Neurology,General Medicine
Reference40 articles.
1. Aguiar S, Dias J, Andre A, Silva M, Martins D, Carrapico B, Castanho M, Carrico J, Cavaco M, Gaspar M, Nobre R, Almeida L, Oliveria S, Gano L, Correia J, Barcas C, Goncalves J, Neves V, Aires-da-Silva F. Highly specific blood–brain barrier transmigrating single-domain antibodies selected by an in vivo phage display screening. Pharmaceutics. 2021;13(10):1598. 2. Ando Y, Okada H, Takemura G, Suzuki K, Takada C, Tomita H, Zaikokuji R, Hotta Y, Miyazaki N, Yano H, Muraki I, Kuroda A, Fukuda H, Kawasaki Y, Okamoto H, Kawauchi T, Watanabe T, Doi T, Yoshida T, Ushikoshi H, Yoshida S, Ogura S. Brain-specific ultrastructure of capillary endothelial glycocalyx and its possible contribution for blood brain barrier. Sci Rep. 2018;8:17523. 3. Ben-Zvi A, Lacoste B, Kur E, Andreone B, Mayshar Y, Yan H, Gu C. Mfsd2a is critical for the formation and function of the blood–brain barrier. Nature. 2014;509(7501):507–11. 4. Bickel U, Yoshikawa T, Pardridge W. Delivery of peptides and proteins through the blood–brain barrier. Adv Drug Deliv Rev. 2001;46(1–3):247–79. 5. Cegarra C, Cameron B, Chaves C, Dabdoubi T, Do T, Genet B, Roudieres V, Shi Y, Tchepikoff P, Lesuisse D. An innovative strategy to identify new targets for delivering antibodies to the brain has led to the exploration of the integrin family. PLoS One. 2022;17(9): e0274667.
|
|